IgG3 and IL10 are effective biomarkers for monitoring therapeutic effectiveness in Post Kala-Azar Dermal Leishmaniasis.

<h4>Background</h4>The assessment of chemotherapeutic responses in Post Kala-azar Dermal Leishmaniasis (PKDL), especially its macular form is challenging, emphasizing the necessity for 'test of cure' tools. This study explored the diagnostic and prognostic potential of IgG subc...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Shilpa Sengupta, Mitali Chatterjee
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Arctic medicine. Tropical medicine RC955-962 Public aspects of medicine RA1-1270
Acceso en línea:	https://doaj.org/article/58950595df3541b587462c42dbf3ea2e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:58950595df3541b587462c42dbf3ea2e
record_format	dspace
spelling	oai:doaj.org-article:58950595df3541b587462c42dbf3ea2e2021-12-02T20:23:31ZIgG3 and IL10 are effective biomarkers for monitoring therapeutic effectiveness in Post Kala-Azar Dermal Leishmaniasis.1935-27271935-273510.1371/journal.pntd.0009906https://doaj.org/article/58950595df3541b587462c42dbf3ea2e2021-11-01T00:00:00Zhttps://doi.org/10.1371/journal.pntd.0009906https://doaj.org/toc/1935-2727https://doaj.org/toc/1935-2735<h4>Background</h4>The assessment of chemotherapeutic responses in Post Kala-azar Dermal Leishmaniasis (PKDL), especially its macular form is challenging, emphasizing the necessity for 'test of cure' tools. This study explored the diagnostic and prognostic potential of IgG subclasses and associated cytokines for monitoring the effectiveness of chemotherapy in PKDL.<h4>Methods</h4>Participants included PKDL cases at (a) disease presentation, (b) immediately at the end of treatment (12 weeks for Miltefosine or 3 weeks for Liposomal Amphotericin B, LAmB and (c) at any time point 6 months later, for estimating anti-leishmanial immunoglobulin (Ig, IgG, IgM, IgG1, IgG2 and IgG3) and cytokines (IL-10, IL-6).<h4>Results</h4>In PKDL, Ig levels were elevated, with IgG3 and IL-10 being the major contributors. Miltefosine decreased both markers substantially and this decrease was sustained for at least six months. In contrast, LAmB failed to decrease IgG3 and IL-10, as even after six months, their levels remained unchanged or even increased.<h4>Conclusions</h4>In PKDL, IgG3 and IL-10 proved to be effective predictors of responsiveness to chemotherapy and may be considered as a non invasive alternative for longitudinal monitoring.Shilpa SenguptaMitali ChatterjeePublic Library of Science (PLoS)articleArctic medicine. Tropical medicineRC955-962Public aspects of medicineRA1-1270ENPLoS Neglected Tropical Diseases, Vol 15, Iss 11, p e0009906 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Arctic medicine. Tropical medicine RC955-962 Public aspects of medicine RA1-1270
spellingShingle	Arctic medicine. Tropical medicine RC955-962 Public aspects of medicine RA1-1270 Shilpa Sengupta Mitali Chatterjee IgG3 and IL10 are effective biomarkers for monitoring therapeutic effectiveness in Post Kala-Azar Dermal Leishmaniasis.
description	<h4>Background</h4>The assessment of chemotherapeutic responses in Post Kala-azar Dermal Leishmaniasis (PKDL), especially its macular form is challenging, emphasizing the necessity for 'test of cure' tools. This study explored the diagnostic and prognostic potential of IgG subclasses and associated cytokines for monitoring the effectiveness of chemotherapy in PKDL.<h4>Methods</h4>Participants included PKDL cases at (a) disease presentation, (b) immediately at the end of treatment (12 weeks for Miltefosine or 3 weeks for Liposomal Amphotericin B, LAmB and (c) at any time point 6 months later, for estimating anti-leishmanial immunoglobulin (Ig, IgG, IgM, IgG1, IgG2 and IgG3) and cytokines (IL-10, IL-6).<h4>Results</h4>In PKDL, Ig levels were elevated, with IgG3 and IL-10 being the major contributors. Miltefosine decreased both markers substantially and this decrease was sustained for at least six months. In contrast, LAmB failed to decrease IgG3 and IL-10, as even after six months, their levels remained unchanged or even increased.<h4>Conclusions</h4>In PKDL, IgG3 and IL-10 proved to be effective predictors of responsiveness to chemotherapy and may be considered as a non invasive alternative for longitudinal monitoring.
format	article
author	Shilpa Sengupta Mitali Chatterjee
author_facet	Shilpa Sengupta Mitali Chatterjee
author_sort	Shilpa Sengupta
title	IgG3 and IL10 are effective biomarkers for monitoring therapeutic effectiveness in Post Kala-Azar Dermal Leishmaniasis.
title_short	IgG3 and IL10 are effective biomarkers for monitoring therapeutic effectiveness in Post Kala-Azar Dermal Leishmaniasis.
title_full	IgG3 and IL10 are effective biomarkers for monitoring therapeutic effectiveness in Post Kala-Azar Dermal Leishmaniasis.
title_fullStr	IgG3 and IL10 are effective biomarkers for monitoring therapeutic effectiveness in Post Kala-Azar Dermal Leishmaniasis.
title_full_unstemmed	IgG3 and IL10 are effective biomarkers for monitoring therapeutic effectiveness in Post Kala-Azar Dermal Leishmaniasis.
title_sort	igg3 and il10 are effective biomarkers for monitoring therapeutic effectiveness in post kala-azar dermal leishmaniasis.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/58950595df3541b587462c42dbf3ea2e
work_keys_str_mv	AT shilpasengupta igg3andil10areeffectivebiomarkersformonitoringtherapeuticeffectivenessinpostkalaazardermalleishmaniasis AT mitalichatterjee igg3andil10areeffectivebiomarkersformonitoringtherapeuticeffectivenessinpostkalaazardermalleishmaniasis
_version_	1718374108482240512

IgG3 and IL10 are effective biomarkers for monitoring therapeutic effectiveness in Post Kala-Azar Dermal Leishmaniasis.

Ejemplares similares